Pranav Gandhi
5PUBLICATIONS
20CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Aug 20, 2025
Long-term safety, efficacy and functional outcomes of atogepant for the preventive treatment of migraine.Sait Ashina, Messoud Ashina, Dagny Holle-Lee
|Dec 23, 2024
Early Improvements With Atogepant for the Preventive Treatment of Migraine: Results From 3 Randomized Phase 3 Trials.Richard B Lipton, Pranav Gandhi, Cristina Tassorelli
|Dec 09, 2024
Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized, phase 3 trials.Christopher Gottschalk, Pranav Gandhi, Patricia Pozo-Rosich
|Nov 19, 2024
Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene-related peptide monoclonal antibodies.Jessica Ailani, Anjana Lalla, Rashmi B Halker Singh
|Aug 28, 2024
Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome: Results From the Randomized PRODROME Trial.Richard B Lipton, Andrea M Harriott, Julia Y Ma
Pageof 1
Frequent Collaborators
3 joint publications
Richard B Lipton
3 joint publications
Cristina Tassorelli
2 joint publications
Andrea M Harriott
2 joint publications
Jonathan H Smith
2 joint publications
Patricia Pozo-Rosich
1 joint publications
Joel M Trugman
1 joint publications
David W Dodick
1 joint publications
Cristiano Piron
1 joint publications
Uwe Reuter
1 joint publications
Dagny Holle-Lee
